#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Derek Sloan Email
VP, Therapeutic Product and Process Development . GenEdit
South San Francisco, CA
LocationPrimary Email
How to contact Derek Sloan
Join and see Derek's contact info for free!Phone
Current Roles
Employees:
57Revenue:
$8.8MAbout
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications. In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, current CRISPR delivery methods rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. A non-viral CRISPR/Cas9 delivery method is needed. In addition, low efficiency levels achieved make it impossible to target certain diseases. GenEdit's novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.GenEdit Address
681 Gateway BlvdSouth San Francisco, CA
United States